Suchergebnisse - "Davies, Jane C"

PubPharm (17)

1

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von McNally, P. | Lester, K. | Stone, G. | +25

CommentIn: Am J Respir Crit Care Med. 2023 Nov 1;208(9):911-913. - PMID 37756441

2

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele : A Phase 3, Open-Label Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von Wainwright, C. | McColley, S. | McNally, P. | +14

CommentIn: Am J Respir Crit Care Med. 2023 Jul 1;208(1):9-11. - PMID 37167625

3

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation : A Phase 3b, Randomized, Placebo-controlled Study

enthalten in: American journal of respiratory and critical care medicine | 2022

von Mall, M. | Brugha, R. | Gartner, S. | +21

CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1308-1310. - PMID 35947636

4

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2022

von Sawicki, G. | Chilvers, M. | McNamara, J. | +10

5

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2021

von Davies, J. | Wainwright, C. | Sawicki, G. | +7

CommentIn: Am J Respir Crit Care Med. 2021 Mar 1;203(5):536-537. - PMID 33113333

6

Entering the era of highly effective modulator therapies

enthalten in: Pediatric pulmonology | 2021

von Dave, K. | Dobra, R. | Scott, S. | +4

7

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2021

von Davies, J. | Sermet-Gaudelus, I. | Naehrlich, L. | +10

8

Monitoring early stage lung disease in cystic fibrosis

enthalten in: Current opinion in pulmonary medicine | 2020

von Nissenbaum, C. | Davies, G. | Horsley, A. | +1

9

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2019

von Rosenfeld, M. | Cunningham, S. | Harris, W. | +10

10

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients : An open-label, single-arm, phase 2a study (SAPHIRA1)

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2019

von Davies, J. | Van de Steen, O. | van Koningsbruggen-Rietschel, S. | +8